Commentary


Nature Biotechnology 26, 889 - 896 (2008)
doi:10.1038/nbt.1411

Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project

Chris F Taylor1,2, Dawn Field2,3, Susanna-Assunta Sansone1,2, Jan Aerts4, Rolf Apweiler1, Michael Ashburner5, Catherine A Ball6, Pierre-Alain Binz7,8, Molly Bogue9, Tim Booth2, Alvis Brazma1, Ryan R Brinkman10, Adam Michael Clark11, Eric W Deutsch12, Oliver Fiehn13, Jennifer Fostel14, Peter Ghazal15, Frank Gibson16, Tanya Gray2,3, Graeme Grimes15, John M Hancock17, Nigel W Hardy18, Henning Hermjakob1, Randall K Julian, Jr19, Matthew Kane20, Carsten Kettner21, Christopher Kinsinger22, Eugene Kolker23,24, Martin Kuiper25, Nicolas Le Novère1, Jim Leebens-Mack26, Suzanna E Lewis27, Phillip Lord16, Ann-Marie Mallon17, Nishanth Marthandan28, Hiroshi Masuya29, Ruth McNally30, Alexander Mehrle31, Norman Morrison2,32, Sandra Orchard1, John Quackenbush33, James M Reecy34, Donald G Robertson35, Philippe Rocca-Serra1,36, Henry Rodriguez22, Heiko Rosenfelder31, Javier Santoyo-Lopez15, Richard H Scheuermann28, Daniel Schober1, Barry Smith37, Jason Snape38, Christian J Stoeckert, Jr39, Keith Tipton40, Peter Sterk1, Andreas Untergasser41, Jo Vandesompele42 & Stefan Wiemann31

To fully understand the context, methods, data and conclusions that pertain to an experiment, one must have access to a range of background information. However, the current diversity of experimental designs and analytical techniques complicates the discovery and evaluation of experimental data; furthermore, the increasing rate of production of those data compounds the problem. Community opinion increasingly favors that a regularized set of the available metadata ('data about the data') pertaining to an experiment1, 2 be associated with the results, making explicit both the biological and methodological contexts. Many journals and funding agencies now require that authors reporting microarray-based transcriptomics experiments comply with the Minimum Information about a Microarray Experiment (MIAME) checklist3 as a prerequisite for publication4, 5, 6, 7. Similarly, minimum information guidelines for reporting proteomics experiments and describing systems biology models are gaining broader support in their respective database communities8, 9; and progress is being made toward the standardization of the reporting of clinical trials in the medical literature10. Such minimum information checklists promote transparency in experimental reporting, enhance accessibility to data and support effective quality assessment, increasing the general value of a body of work (and the competitiveness of the originators).

Collaborative minimum information checklist development projects for diverse biologically and technologically delineated subject areas are ongoing. A special issue of the journal OMICS11 included invited pieces from eight communities supporting minimum information checklist development projects. However, until recently there were no mechanisms for such projects to coordinate their development. Consequently, the full range of checklists can be difficult to establish without intensive searching, and tracking their evolution is nontrivial. Furthermore, overlaps in scope and arbitrary decisions on wording and substructuring inhibit their use in combination. These issues present difficulties for checklist users, especially those who routinely combine information from several disciplines. Here we explore some of the issues arising from the development of checklists in relative isolation, discuss the potential benefits of greater coordination and describe the mechanisms we have put in place to facilitate such coordination. In summary, we present the MIBBI project (http://www.mibbi.org/), which maintains a web-based, freely accessible resource for checklist projects, providing straightforward access to extant checklists (and to complementary data formats, controlled vocabularies, tools and databases), thereby enhancing both transparency and accessibility, as discussed above. MIBBI is managed by representatives of its various participant communities and is fully open to comment from any interested party. Our goal is to facilitate the development of an integrated checklist resource site for the wider bioscience community.

On the need to harmonize minimum information checklists

The current proliferation of documents specifying the minimum information to provide when reporting particular kinds of experimental data has in large part been driven by the advent of a range of so-called 'omics' (and allied) technologies, many of which operate in a high-throughput mode, thereby generating large volumes of data. These documents have been developed independently for the most part, and as a result feature many arbitrary differences in both wording and structure. This greatly complicates the integration of data sets that comply with different minimum information checklists. Increasing appreciation of the potential value accruing to 'secondary use' of data is also a significant factor8, reflecting the general increase in frequency of data-driven (as opposed to hypothesis-driven) investigations in recent years. These trends have together made the need for coordination and harmonization between groups developing data format and reporting standards a critical issue10. Throughout this document, the words 'standard' and 'standardization' are used to refer only to the regularization of data capture, representation, annotation or reporting, as opposed to best practices for experimental procedures. Specifically, we refer to three kinds of reporting standards: (i) minimum information checklists or guidelines; (ii) formats (syntax); and (iii) controlled vocabularies and ontologies (semantics).

It is clear that checklists should be developed through close consultation with their sponsoring practitioner communities, but such checklists should also, we believe, be designed to anticipate 'cross-domain' integrative activities. It is unhelpful to confine checklists for the use of particular technologies to a limited set of biologically delineated communities, or to conceive of any such community as being restricted to a particular set of technologies. Consider mass spectrometry, which is used in the study of proteins, metabolites and even to sequence genes; or consider toxicology, which may use any or all of the available 'omics' technologies in pursuit of the greater understanding of the mode of action of a particular compound. Clearly the vistas from any two locations can overlap substantially, so who can claim sole ownership of any part of the scientific landscape? Initiatives such as that to harmonize the description of 'sample' (the biological source material for a study)12 or to develop (separable) community-level extensions to shared core standards such as MIAME to better describe domain-specific studies (for example, in environmental biology13) are clearly the order of the day. This throws into relief an important division between analytical approaches and the various subdivisions of the biosciences. Checklists that do not span that division will always achieve greater utility because they can be reused more straightforwardly to construct new, made-to-order checklists for a wider range of workflows.

The management of information from experiments (both data and metadata) requires the adoption of reporting standards that ensure transparency and interoperability and that facilitate the integration and exchange of data from different sources. Reporting standards also facilitate the execution of more powerful queries against repositories of experimental data because core information will be regularized and extended information will be supplied in a well characterized manner. This long-term vision will require significant effort and buy-in from a range of scientific communities spread across many nations, but development of some of the kinds of component required to establish such infrastructure is well underway: Functional Genomics Experiment14 (FuGE) is an object-oriented data model (with an associated XML-based syntactic format) capable of capturing a wide range of (meta)data in a consistent manner; Reporting Structure for Biological Investigations (RSBI)15 provides a foundational lingua franca for standards projects (described further below) and builds on this to define a simple, but general, tabular format (ISA-TAB)16 aligned with FuGE; Ontology for Biomedical Investigations (OBI; http://obi.sourceforge.net/) is a broad-scope ontology providing a self-compatible set of terms with which to describe a wide range of biological and medical studies; and the Open Biomedical Ontologies (OBO) Foundry17 (http://obofoundry.org/) coordinates the development of a set of 'gold-standard reference ontologies' (including OBI) that can be used in combination because they are based on common principles and, importantly, because procedures have been established to ensure resolution of the conflicts that might arise where ontologies overlap.

ADVERTISEMENT

Although the primary purpose of minimum information checklists is to guide researchers in reporting their experiments, they can, for the kinds of projects mentioned above, serve a valuable role as key 'use cases', in that they represent the distilled opinion of a particular community on the information that should normally be captured to effectively describe a particular kind of experiment. They therefore provide a realistic scenario with which to test any resource's suitability for use by a community; for example, for software and database developers to ensure that their products can handle the specified data appropriately; or for instrument vendors to offer checklist-compliant data set export from their instrument management software. It is also likely that journals and funders will adopt some checklists wholesale, incorporating them into their guidance for authors and applicants.

A resource for minimum information checklists: MIBBI

The activities of standardization groups often go unpublished and may not be accessible at all, practically speaking. A common resource for minimum information checklists, coordinated by a group of community representatives from ongoing standardization activities, will help unify the standardization community. It will assist in recruiting participants to ongoing activities and it will help to maintain transparency of process by providing access to project-related information (for example, status, key players and plans). It will also ease the establishment of new initiatives by providing answers to questions such as, "How do we get started?" and, importantly, "How do we make sure we don't reinvent the wheel?". Such an effort will improve communication, knowledge transfer and integration between checklist development projects hailing from different scientific communities and, further, between different kinds of reporting standards projects, ultimately resulting in simplified access to a broad range of richly annotated data for the end user. Thus, we have established the MIBBI project—a web-based, communal resource designed to act as a 'one-stop shop' for those exploring the range of extant checklist projects and to foster collaborative, integrative development of checklists (http://www.mibbi.org/).

MIBBI has two key parts. The first is the 'Portal', which exists simply to raise awareness of, and afford more straightforward access to, a wide range of checklists by providing researchers, journal editors, reviewers, funders and the wider community of checklist developers with a quick and simple way to discover (whether there is) a checklist addressing a particular area and to establish the scope and progress of the underlying project. The Portal provides summary information for each of the MIBBI-affiliated projects; specifically, the primary contact(s) and website (where available), an overview of the project's scope and developmental status and links to publications and other documents (including, where possible, a link to the most recent version of that project's checklist). Information available through the Portal will be updated as circumstances change (for example, if a project is fragmented or amalgamated, or simply becomes dormant). Box 1 offers brief textual descriptions of the 21 projects currently registered with MIBBI; Table 1 provides a representation of the concepts that comprise each project's scope, along with their checklist's developmental status and, where applicable, an indication that a checklist is composed of separate modules.


By signing up with the MIBBI Portal and thereby attracting more intensive peer oversight, communities will come under pressure to maintain their checklists in light of scientific advances, to provide open access to their processes and to respond to comments. We hope that one of the primary benefits of the Portal will be to raise awareness in the biological and medical communities of the importance of standardization, thereby increasing willingness among researchers to become involved in guiding and shaping the evolution of these activities. We hope it will help push the community to strive for compliance in their own publication and data-dissemination practices by facilitating access to relevant information about these efforts. We also see this as an excellent artifact with which to promote collaboration within and between communities: the principle we endorse is that if a broadly relevant effort already exists (for example, describing the use of a particular technology), individuals with an interest should seek to join that effort rather than compete with it. However, it is crucial that MIBBI never preclude revisions or innovations; the hoped-for kudos and enhanced coordination accruing to membership should not translate to a possible dominion.

The second key part of MIBBI is the 'Foundry'. Communities can, if motivated, sign up with the Foundry to jointly examine ways to refactor the checklists over which they have control and then to develop a suite of self-consistent, clearly bounded, orthogonal, integrable checklist modules. These modules will then be made available to the community through the MICheckout tool, a collaborative development between the European Bioinformatics Institute and the UK Natural Environmental Research Council's Environmental Bioinformatics Centre. MICheckout will assist users in compiling the correct list of modules and downloading them in a form that they can use. Note that registering a project with MIBBI implies no commitment by a project to participate in the Foundry activity. Furthermore, attempts to integrate checklists through the Foundry should be managed through a community-driven mechanism that relies primarily on openness and transparency to encourage (voluntary) uptake. The MIBBI Foundry is modeled on the OBO Foundry17, a newly established initiative in the field of ontology development. Communities working together through MIBBI will produce orthogonal (that is, non-overlapping) minimum information modules, just as the communities involved with the OBO Foundry are aiming to produce orthogonal ontologies.

Foundry activities must be driven by the member communities (acting through their representatives). In preparation for the Foundry activity, we have established discussion forums to facilitate communication between communities to encourage discussion of the overlaps between checklists. Exploratory studies are ongoing, based on coarse comparison tables (such as Table 1) that highlight areas addressed by one or more projects. The next stage is to use 'groupware' (that is, a wiki or an online document-sharing tool) to jointly develop modules for those shared areas. Throughout this gradually intensifying activity, we will hold regular face-to-face meetings that act as development workshops and promote good working relationships between project representatives. The first such meeting was held in April 2008 at the European Bioinformatics Institute and was funded by the UK's Biotechnology and Biological Sciences Research Council. This first meeting rapidly reached consensus on a work plan and established working groups to begin to generate MIBBI Foundry modules. A full workshop report is available through the project's website (http://www.mibbi.org/).

High-level abstractions of the components of experimental workflows offer a useful framework to support the integration of checklists. An example of a group attempting to produce such abstractions is the RSBI working group14, which interacts with a number of other initiatives18, 19, 20 in working toward an integrated view of functional genomics investigations. In their characterization, an 'Investigation' is a self-contained unit of scientific enquiry, with a holistic hypothesis or objective and a design that is defined by the relationships between one or more 'Studies' and 'Assays'. A Study represents the part of an experiment containing information about the biological material, and an Assay is the part using particular technologies that produce data. The RSBI's proposed framework of well defined, high-level abstractions (such as the three just described) was developed because the above concepts are duplicated, but differently named, across different checklists, confounding the uniform description of the diverse events that may occur within a Study (sensu RSBI).

Foundational analysis of MIBBI-registered projects

To better understand the scope and depth of the various MIBBI-registered minimum information checklists, we performed a comparative analysis. Table 1 presents a projection of the various checklists onto a coarse-grained list of ad hoc concepts, constructed exclusively for the purpose of identifying overlaps between those existing checklists; note that the concepts vary widely in breadth of scope (see Box 2), so the number of concepts addressed by any one project is not necessarily indicative of the size of that project's guidelines, as some concepts cover whole workflows (for example, 'nucleic acid sequencing'). It will be clear to the reader that some of these concepts, such as 'organism', are almost universal, whereas others, such as 'quantitative PCR amplification', may relate to one group alone. It is also clear that the depth of description required in relation to particular concepts varies widely across projects, suggesting a 'tiered' approach; that is, some of the checklist modules generated by the MIBBI Foundry should, in some cases, require a different depth of description contingent on the particular experimental context. Row and column totals (summing presence or absence only) are provided in Table 1; the row totals have been used to rank-order concepts by 'popularity'. Figure 1 lists the eighteen most common ad hoc concepts.

Figure 1: The eighteen highest-ranked ad hoc concepts, according to Table 1.

Figure 1 : The eighteen highest-ranked ad hoc concepts, according to Table 1.

This highlights priority areas for the MIBBI Foundry (though the concepts used here may not directly translate into guidelines modules).

Full size image (32 KB)

To support greater understanding of the relatedness of the different projects and of the various ad hoc concepts, we conducted two pairwise comparisons using the data presented in Table 1: concepts 'shared' between pairs of projects, and pairs of concepts occurring together within projects (counting presence or absence only). Supplementary Figure 1 online illustrates the interrelatedness of the 21 MIBBI-registered projects both as a tree and as an interaction graph. These two representations make clear that there is a subset of closely related (that is, heavily overlapping) projects; these are, broadly speaking, the 'technologically delineated' projects, such as MIAME and the Minimum Information About Proteomics Experiment (MIAPE). It is also clear that there are many projects that are 'related' (according to the tree, if considered in isolation) only by their low degree of relatedness to any other project (as the interaction graph makes explicit). Supplementary Figure 2 online presents an unrooted tree expressing the relatedness of individual concepts. Although this analysis is based on the various projects' scopes, rather than any sense of the similarity of the concepts themselves, it produces some sensible-looking groupings. All the highly ranked ('high-priority') concepts from Figure 1 cluster together because most of the projects share an interest in many of them, so they are often found to occur together in individual projects' scopes. Such an analysis can help in deciding how the ad hoc concept-based survey presented in Table 1 should be used as we draft the checklist modules that will ultimately be developed by participants in the MIBBI Foundry's activities (that is, whether some concepts can be combined, whether others should be further subdivided, and so on).

These various analyses make two things plain: first, that there are standout priority areas for the MIBBI Foundry (for example, the uniform description of an organism); and second, that there are many niche areas where little or no collaborative activity is required (for example, the process of mouse phenotyping)—a simple endorsement by MIBBI of the products of a particular project being sufficient, as things stand.

Conclusions

By providing easy access to checklist development projects and their products, MIBBI will facilitate the discovery of checklists appropriate to the needs of practitioners from diverse parts of biological and biomedical science (the 'one-stop shop' principle). The widespread availability of well-annotated data sets, ensuant to the routine use of minimum information checklists, will increase secondary use of data and allow for a more thorough assessment of the worth of a body of work, making for more efficient and effective science.

MIBBI will increase connectivity between minimum information checklist projects and, more widely, will increase connectivity with projects developing other kinds of informatics resources (formats, vocabularies, tools, databases). The resultant evolution of an interdisciplinary community of checklist developers will bring into focus the collective expertise residing in that group. It will accelerate the establishment of mutually beneficial networks of expertise, and it will advance (through the MIBBI Foundry, building on the foundational analysis presented here) our long-term vision of a fully integrated, broad-coverage suite of minimum information checklists, in step with the general movement in the biological and medical sciences toward integrated, multifaceted investigations of the puzzles that remain to be addressed in the postgenomic era.

Author contributions

D.F., S.-A.S. and C.F.T. conceived and designed the concept of MIBBI as synergistic project; D.F. and S.-A.S. raised the funds to support MIBBI activities, and C.F.T. performed the analysis presented in this paper; all authors discussed the results and implications and commented on the manuscript.

Note: Supplementary information is available on the Nature Biotechnology website.



Top

Acknowledgments

We. acknowledge funding from the UK Natural Environmental Research Council's Environmental Bioinformatics Centre and the UK Biotechnology and Biological Sciences Research Council (BB/E025080/1) to D.F. and S.-A.S. to support C.F.T. and MIBBI. Work on MIFlowCyt is supported by the US National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering (EB005034-01) and by Bioinformatics Integration Support Contract A140076 from the US National Institute of Allergy and Infectious Diseases. R.R.B. is supported by the Michael Smith Foundation for Health Research, by the International Society for the Advancement of Cytology and by grant funding from the US National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health (R01EB005034). N.W.H. acknowledges the support of the European Union Framework VI project META-PHOR (Food-ST-2006-03622). F.G., P.L. and work on CARMEN are supported by the UK Engineering and Physical Sciences Research Council (EP/E002331/1). K.T. acknowledges support from Science Foundation Ireland. Work on MIAME/Tox and MIAME/Nutr by P.R-S. is supported by the NuGO (NoE 503630) and CarcinoGenomics (PL 037712) European Union projects. Work on MIARE is supported by the eDIKT project. Opinions, findings and conclusions or recommendations expressed in this paper are those of the authors and do not necessarily reflect the views of the US National Science Foundation or the US National Institutes of Health.

Competing interests statement:

The authors declare  competing financial interests.

Top

References

  1. Quackenbush, J. Standardizing the standards. Mol. Syst. Biol. 2, 2006.0010 (2006).
  2. Anonymous. Under the MIAME sun. Nat. Methods 3, 415 (2006). | Article |
  3. Brazma, A. et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat. Genet. 29, 365–371 (2001). | Article | PubMed | ISI | ChemPort |
  4. Anonymous. Microarray standards at last. Nature 419, 323 (2002). | Article | ISI |
  5. Ball, C.A. et al. A guide to microarray experiments—an open letter to the scientific journals. Lancet 360, 1019 (2002). | Article | ISI |
  6. Ball, C.A. et al. Standards for microarray data. Science 298, 539 (2002). | Article | PubMed | ISI | ChemPort |
  7. Ball, C.A. et al. The underlying principles of scientific publication. Bioinformatics 18, 1409 (2002). | Article | PubMed | ISI | ChemPort |
  8. Taylor, C.F. et al. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 25, 887–893 (2007). | Article | PubMed | ISI | ChemPort |
  9. Le Novère, N. et al. Minimum information requested in the annotation of biochemical models (MIRIAM). Nat. Biotechnol. 23, 1509–1515 (2005). | Article | PubMed | ISI | ChemPort |
  10. Altman, D.G., Simera, I., Hoey, J., Moher, D. & Schulz, K. EQUATOR: reporting guidelines for health research. Lancet 371, 1149–1150 (2008). | Article | PubMed |
  11. Field, D. & Sansone, S.-A. A special issue on data standards. OMICS 10, 84–93 (2006). | Article | PubMed | ISI | ChemPort |
  12. Morrison, N. et al. Concept of sample in OMICS technology. OMICS 10, 127–137 (2006). | Article | PubMed | ChemPort |
  13. Morrison, N. et al. Standard annotation of environmental OMICS data: application to the transcriptomics domain. OMICS 10, 172–178 (2006). | Article | PubMed | ChemPort |
  14. Jones, A.R. et al. The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat. Biotechnol. 25, 1127–1133 (2007). | Article | PubMed | ChemPort |
  15. Sansone, S.-A. et al. A strategy capitalizing on synergies: the Reporting Structure for Biological Investigation (RSBI) working group. OMICS 10, 164–171 (2006). | Article | PubMed | ISI | ChemPort |
  16. Sansone, S.-A. et al. The first RSBI (ISA-TAB) workshop: "Can a simple format work for complex studies?" OMICS published online, doi:doi: 10.1089/omi.2008.0019 (2008). | Article |
  17. Smith, B. et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat. Biotechnol. 25, 1251–1255 (2007). | Article | PubMed | ChemPort |
  18. Taylor, C.F. et al. The work of the Human Proteome Organisation's Proteomics Standards Initiative (HUPO PSI). OMICS 10, 145–151 (2006). | Article | PubMed | ISI | ChemPort |
  19. Fiehn, O. et al. Establishing reporting standards for metabolomic and metabonomic studies: a call for participation. OMICS 10, 158–163 (2006). | Article | PubMed | ChemPort |
  20. Field, D. et al. The minimum information about a genome sequence (MIGS) specification. Nat. Biotechnol. 26, 541–547 (2008). | Article | PubMed | ChemPort |
  21. Deutsch, E.W. et al. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat. Biotechnol. 26, 305–312 (2008). | Article | PubMed | ChemPort |
  1. European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.
  2. Natural Environment Research Council Environmental Bioinformatics Centre, Mansfield Road, Oxford OX1 3SR, UK.
  3. Molecular Evolution and Bioinformatics Group, Oxford Centre for Ecology and Hydrology, Mansfield Road, Oxford OX1 3SR, UK.
  4. Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK.
  5. Department of Genetics, University of Cambridge, Downing Street, Cambridge CB2 3EH, UK.
  6. Stanford Microarray Database, Department of Biochemistry, Stanford University School of Medicine, Stanford, California 94305-5307, USA.
  7. Swiss Institute of Bioinformatics, Michel-Servet 1, 1211 Geneva, Switzerland.
  8. Geneva Bioinformatics (GeneBio) SA, Avenue de Champel 25, 1206 Geneva, Switzerland.
  9. Jax Mouse Phenome Project, The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609, USA.
  10. Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver V5Z 1L3, British Columbia, Canada.
  11. The Lance Armstrong Foundation, PO Box 161150, Austin, Texas 78716-1150, USA.
  12. Institute for Systems Biology, 1441 N. 34th Street, Seattle, Washington 98103, USA.
  13. University of California Davis, Genome Center, 451 East Health Sciences Drive, Davis, California 95616, USA.
  14. National Institute of Environmental Health Sciences and Lockheed Martin Information Technology, Research Triangle Park, North Carolina 27709-2233, USA.
  15. Division of Pathway Medicine, University of Edinburgh Medical School, The Chancellor's Building, Little France Crescent, Edinburgh EH16 4SB, UK.
  16. School of Computing Science, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
  17. Bioinformatics Group, Medical Research Council Mammalian Genetics Unit, Harwell, Oxfordshire OX11 0RD, UK.
  18. Department of Computer Science, Aberystwyth University, Penglais, Aberystwyth SY23 3DB, UK.
  19. Indigo BioSystems, Inc., 111 Congressional Boulevard, Suite 160, Carmel, Indiana 46032, USA.
  20. Division of Molecular and Cellular Biosciences, National Science Foundation, 4201 Wilson Boulevard, Arlington, Virginia 22230, USA.
  21. Beilstein-Institut zur Förderung der Chemischen Wissenschaften, Trakehner Strasse 7-9, D-60487 Frankfurt am Main, Germany.
  22. Office of Technology and Industrial Relations, Office of the Director, National Cancer Institute, Bldg 31A, Rm 10A52, Bethesda, Maryland 20892, USA.
  23. Seattle Children's Hospital Research Institute, 1900 9th Avenue, Seattle, Washington 98101, USA.
  24. Seattle Children's Hospital and Regional Medical Center, 4800 Sand Point Way NE, Seattle, Washington 98105, USA.
  25. Department of Plant Systems Biology, Vlaams Instituut voor Biotechnologie, Technologiepark 927, B-9052 Ghent, Belgium; Molecular Genetics, Ghent University, B-9052 Ghent, Belgium; and Department of Biology, Norwegian University of Science and Technology, N-7491 Trondheim, Norway.
  26. Department of Plant Biology, University of Georgia, Athens, Georgia 30602-7271, USA.
  27. Department of Molecular and Cellular Biology, Life Sciences Addition, University of California, Berkeley, California 94729-3200, USA.
  28. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 USA.
  29. RIKEN Genomic Sciences Center, 3-1-1 Koyadai, Tsukuba-shi, Ibaraki 305-0074 Japan.
  30. Economic and Social Research Council Centre for Economic and Social Aspects of Genomics (Cesagen), Lancaster University, Institute for Advanced Studies, IAS Building, County South, Lancaster LA1 4YD, UK.
  31. Division of Molecular Genome Analysis, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany.
  32. School of Computer Science, University of Manchester, Oxford Road, Manchester M13 9PL, UK.
  33. Department of Biostatistics and Computational Biology and Department of Cancer Biology, Dana-Farber Cancer Institute, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
  34. Department of Animal Science, Center for Integrated Animal Genomics, Iowa State University, 2255 Kildee Hall, Ames, Iowa 50011-3150, USA.
  35. Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey 08543-4000, USA.
  36. NuGO, The European Nutrigenomics Organisation (http://www.nugo.org/).
  37. Department of Philosophy and Center of Excellence in Bioinformatics and Life Sciences, University at Buffalo, New York 14260, USA.
  38. AstraZeneca UK Ltd., Brixham, Devon TQ5 8BA, UK.
  39. Department of Genetics, Center for Bioinformatics, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021, USA.
  40. School of Biochemistry and Immunology, Trinity College Dublin, College Green, Dublin 2, Ireland.
  41. Laboratory of Molecular Biology, Department of Plant Science, Wageningen University, The Netherlands.
  42. Center for Medical Genetics, Ghent University Hospital, 9000 Ghent, Belgium.

Correspondence to: Chris F Taylor1,2 e-mail: chris.taylor@ebi.ac.uk

Correspondence to: Dawn Field2,3 e-mail: dfield@ceh.ac.uk

Correspondence to: Susanna-Assunta Sansone1,2 e-mail: sansone@ebi.ac.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Standardizing the standards

Molecular Systems Biology News and Views (21 Feb 2006)


Extra navigation

Open Innovation Challenges

naturejobs

ADVERTISEMENT